Clinical Trials

A Phase 3, Double-Blind, Placebo-Controlled Study Of Quizartinib (AC220) In Combination with Induction and Consolidation Chemotherapy, and Maintenance Therapy in Patients 18 To 70 Years Old with Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia


Study ID
Daiichi Sankyo AC220-A-U302

NCT Number
NCT02668653 (Click on the NCT number for more information about the trial)

Research Study Number
2016-0169

Principle Investigator
Dr. Jamie Koprivnikar

Phase
III

Sponsor
Daiichi Sankyo


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now